KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Cash (2016 - 2025)

Nektar Therapeutics has reported Change in Cash over the past 16 years, most recently at -$25.9 million for Q4 2025.

  • Quarterly results put Change in Cash at -$25.9 million for Q4 2025, down 283.24% from a year ago — trailing twelve months through Dec 2025 was -$29.1 million (down 424.64% YoY), and the annual figure for FY2025 was -$29.1 million, down 424.64%.
  • Change in Cash for Q4 2025 was -$25.9 million at Nektar Therapeutics, down from -$2.0 million in the prior quarter.
  • Over the last five years, Change in Cash for NKTR hit a ceiling of $42.8 million in Q1 2022 and a floor of -$98.3 million in Q3 2021.
  • Median Change in Cash over the past 5 years was -$3.7 million (2025), compared with a mean of -$9.2 million.
  • Biggest five-year swings in Change in Cash: crashed 4061.15% in 2021 and later soared 337.96% in 2022.
  • Nektar Therapeutics' Change in Cash stood at -$28.8 million in 2021, then skyrocketed by 39.13% to -$17.5 million in 2022, then crashed by 69.09% to -$29.6 million in 2023, then surged by 147.71% to $14.1 million in 2024, then tumbled by 283.24% to -$25.9 million in 2025.
  • The last three reported values for Change in Cash were -$25.9 million (Q4 2025), -$2.0 million (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.